Results 111 to 120 of about 54,075 (219)

A degrader of HER2 and EGFR abolishes p95HER2 and shows robust antitumor efficacy in HER2-positive breast cancer. [PDF]

Sci Rep
Yang L, Bhattacharya A, Li Y, Peterson D, Zhang Y.   +4 more
europepmc   +1 more source

Spatial Multiomics Reveal Insights Into ADC Efficacy

European Journal of Immunology, Volume 56, Issue 5, May 2026.
Spatial multiomics profiling can reveal how tumor heterogeneity and microenvironment influence ADC efficacy. Combining spatial transcriptomics, proteomics, and AI‐based analysis improves the identification of tissue factors influencing therapy response.
Osman Goni, Niklas Klümper, Maria del Mar Muñiz Moreno, Markus Eckstein, Christoph Kuppe   +4 more
wiley   +1 more source

Targeted Therapies for Each Subtype of Breast Cancer. [PDF]

MedComm (2020)
Liu A, Peng P, Zhu Y, Fei Q, Liu W, Zhang S.   +5 more
europepmc   +1 more source

Nanotechnology Meets Immunotherapy: Crosstalks Against Cancer

Immunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.
ABSTRACT Background The convergence of nanotechnology and immunotherapy has ushered in a transformative era in cancer treatment, offering new strategies to overcome pharmacokinetic limitations and immune evasion associated with conventional therapies. While immunotherapy, spanning checkpoint inhibitors, adoptive cell transfer, and cancer vaccines, has ...
Nima Javanmehr, Asal Moazzami Ashtyani, Robabehbeygom Ghafelehbashi, Fateme Mousavi, Hossein Teimouri   +4 more
wiley   +1 more source

In Vivo Auto-tuning of Antibody-Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies. [PDF]

Mol Cancer Ther
Kopp A, Dong S, Kwon H, Wang T, Desai AA, Philippart A, Koo DJ, Linderman JJ, Tessier PM, Thurber GM.   +9 more
europepmc   +1 more source

RNA Modifications: Current Understandings and Future Perspectives

MedComm, Volume 7, Issue 5, May 2026.
Types of RNA modification. We have summarized the currently common types of RNA modifications, including ac4C, m6A, m1A, m5C, m3C, m7G, and ψ, and visually characterized their features through structural formulas. The characteristic structures are marked with a background color different from the background color.
Shiyu Xiao, Tingwen Xiang, Chuan Yang, Xiaohua Wang, Gang Huang, Fei Luo, Zhao Xie, Yueqi Chen   +7 more
wiley   +1 more source

Updated cost comparison of home care subcutaneous versus outpatient intravenous trastuzumab for HER2-positive breast cancer in Singapore. [PDF]

Ther Adv Med Oncol
Ouyang Y, Ng YT, Hong WW, Graves N.
europepmc   +1 more source

Nonclassical MHC‐I Molecules: Emerging Therapeutic Targets in Next‐Generation Immunotherapy

MedComm, Volume 7, Issue 5, May 2026.
Immunotherapies dependent on classical MHC‐I molecules face significant challenges, including extreme polymorphism and frequent downregulation in pathological conditions. This review discusses how nonclassical MHC‐I molecules (HLA‐E, HLA‐F, HLA‐G, CD1, MR1) may potentially circumvent these limitations through restricted genetic diversity, stable ...
Wanlin He, Andrew J. McMichael
wiley   +1 more source

Overcoming Trastuzumab-Pertuzumab Resistance and Optimizing Sequential Anti-HER2 Therapy in HER2-Positive Metastatic Breast Cancer. [PDF]

Cancers (Basel)
Yamamoto Y.
europepmc   +1 more source

Identifying the Initiation of a New Line of Therapy for Metastatic Lung, Breast, and Colorectal Cancer in Real‐World Data: A Scoping Review

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 5, May 2026.
ABSTRACT Purpose This study aimed to identify and synthesize published algorithms for identifying the initiation of a new line of therapy (LOT) for metastatic lung, breast, and colorectal cancer in real‐world data (RWD). Methods We conducted a scoping review of published, English‐language studies describing algorithms for identifying any LOTs with ...
Oluwadamilola Onasanya, Seyed Hamidreza Mahmoudpour, Benjamin Bates, Irene M. Shui, Geoffrey Liu, Eng Hooi Tan, Yi‐Hsin Yang, Maribel Salas, Joseph Fadare, Dimitri Bennett, Paula Lana de M. Drummond, Judy Ju‐Young Shin, Sonia Guleria, Jocelyn R. Wang, Manila Hada, Helene Denis, Soko Setoguchi, Ilse Truter, Luciane C. Lopes, Ruth Wangia Dixon   +19 more
wiley   +1 more source